Abstract submissions for ACC Quality Summit 2026, taking place Sept. 16-18, 2026, in Orlando, FL, are now open! All members of the cardiovascular and quality team are invited to share their work ...

A traditional Chinese mind-body practice that combines slow, structured movement, deep breathing and meditative focus lowered blood pressure as effectively as brisk walking in a large randomized ...

A new joint guideline published today from the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America, increases the focus on preventing heart failure ...

The ACC is pleased to announce the recipients of its 2026 Distinguished Awards. This year's honorees represent an exceptional group of individuals whose past and ongoing efforts have made meaningful ...

Among patients with severe left ventricular (LV) dysfunction and severe coronary heart disease undergoing complex PCI, elective LV unloading with a microaxial flow pump did not reduce the risk of ...

The PCSK9 inhibitor evolocumab reduced the risk of a first major cardiovascular event in patients with diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis ...

A monthly dose of the novel drug tonlamarsen significantly reduced plasma angiotensinogen (AGT) levels in patients with uncontrolled hypertension compared with a single dose of the drug followed by a ...

Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study ...

Sotatercept, an activin signaling inhibitor, was associated with significant improvements in blood pressure and vascular health in patients with heart failure with preserved ejection fraction (HFpEF) ...

In this week’s View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework ...

The OCEAN Trial found that rivaroxaban did not significantly reduce the incidence of stroke, systemic embolism, or new covert embolic events compared with aspirin in patients at high risk for stroke ...

When compared with angiography-guided PCI, IVUS-guided PCI was found to be not superior in patients with complex coronary arteries according to results from the IVUS-CHIP trial or in patients with ...